Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy

Abstract The current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with AL...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Akihiro Tsukahara, Takafumi Hosokawa, Daisuke Nishioka, Takuya Kotani, Shimon Ishida, Tohru Takeuchi, Fumiharu Kimura, Shigeki Arawaka
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/180446ff808942cb8cb510265dfddfc2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:180446ff808942cb8cb510265dfddfc2
record_format	dspace
spelling	oai:doaj.org-article:180446ff808942cb8cb510265dfddfc22021-11-28T12:18:49ZNeuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy10.1038/s41598-021-02310-22045-2322https://doaj.org/article/180446ff808942cb8cb510265dfddfc22021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02310-2https://doaj.org/toc/2045-2322Abstract The current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with ALS, 23 with CSM, 28 controls, and 10 with Parkinson’s disease (PD) who underwent analysis of CSF NSE levels. The control group comprised patients aged above 45 years who underwent lumbar puncture because of suspected neurological disorders that were ruled out after extensive investigations. CSF NSE levels were evaluated using the electro-chemiluminescent immunoassay. The ALS group had significantly higher CSF NSE levels than the CSM and control groups (P < 0.001 for both comparisons). The CSM, control, and PD groups did not significantly differ in terms of CSF NSE levels. A receiver-operating characteristic curve analysis was performed to assess the diagnostic value of CSF NSE levels in distinguishing ALS from CSM. The area under the curve for CSF NSE levels was 0.86. The optimal cutoff value was 17.7 ng/mL, with a specificity of 87% and a sensitivity of 80%. Hence, CSF NSE levels are elevated in ALS and are effective in distinguishing ALS from CSM.Akihiro TsukaharaTakafumi HosokawaDaisuke NishiokaTakuya KotaniShimon IshidaTohru TakeuchiFumiharu KimuraShigeki ArawakaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Akihiro Tsukahara Takafumi Hosokawa Daisuke Nishioka Takuya Kotani Shimon Ishida Tohru Takeuchi Fumiharu Kimura Shigeki Arawaka Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
description	Abstract The current study aimed to evaluate whether cerebrospinal fluid (CSF) neuron-specific enolase (NSE) levels are elevated in amyotrophic lateral sclerosis (ALS) and are effective in distinguishing ALS from cervical spondylotic myelopathy (CSM). We retrospectively evaluated 45 patients with ALS, 23 with CSM, 28 controls, and 10 with Parkinson’s disease (PD) who underwent analysis of CSF NSE levels. The control group comprised patients aged above 45 years who underwent lumbar puncture because of suspected neurological disorders that were ruled out after extensive investigations. CSF NSE levels were evaluated using the electro-chemiluminescent immunoassay. The ALS group had significantly higher CSF NSE levels than the CSM and control groups (P < 0.001 for both comparisons). The CSM, control, and PD groups did not significantly differ in terms of CSF NSE levels. A receiver-operating characteristic curve analysis was performed to assess the diagnostic value of CSF NSE levels in distinguishing ALS from CSM. The area under the curve for CSF NSE levels was 0.86. The optimal cutoff value was 17.7 ng/mL, with a specificity of 87% and a sensitivity of 80%. Hence, CSF NSE levels are elevated in ALS and are effective in distinguishing ALS from CSM.
format	article
author	Akihiro Tsukahara Takafumi Hosokawa Daisuke Nishioka Takuya Kotani Shimon Ishida Tohru Takeuchi Fumiharu Kimura Shigeki Arawaka
author_facet	Akihiro Tsukahara Takafumi Hosokawa Daisuke Nishioka Takuya Kotani Shimon Ishida Tohru Takeuchi Fumiharu Kimura Shigeki Arawaka
author_sort	Akihiro Tsukahara
title	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
title_short	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
title_full	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
title_fullStr	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
title_full_unstemmed	Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
title_sort	neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/180446ff808942cb8cb510265dfddfc2
work_keys_str_mv	AT akihirotsukahara neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT takafumihosokawa neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT daisukenishioka neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT takuyakotani neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT shimonishida neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT tohrutakeuchi neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT fumiharukimura neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy AT shigekiarawaka neuronspecificenolaselevelisausefulbiomarkerfordistinguishingamyotrophiclateralsclerosisfromcervicalspondyloticmyelopathy
_version_	1718408061546135552

Neuron-specific enolase level is a useful biomarker for distinguishing amyotrophic lateral sclerosis from cervical spondylotic myelopathy

Ejemplares similares